LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 15 of 15: Calculated dose-response metrics. - Dataset (ID:20252)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | GR_AOC |
---|---|---|
SK-BR-3 | Buparlisib | 0.8877 |
SK-BR-3 | BX-912 | 0.7706 |
SK-BR-3 | Alpelisib | 0.4442 |
SK-BR-3 | Canertinib | 1.0665 |
SK-BR-3 | Celastrol | 0.8600 |
SK-BR-3 | CGP60474 | 1.1468 |
SK-BR-3 | CHIR-99021 | 0.2680 |
SK-BR-3 | CP466722 | 0.0472 |
SK-BR-3 | CP724714 | 0.8140 |
SK-BR-3 | Crizotinib | 0.4335 |
SK-BR-3 | Momelotinib | 0.3411 |
SK-BR-3 | Dasatinib | 0.3036 |
SK-BR-3 | Dovitinib | 0.5306 |
SK-BR-3 | Enzastaurin | -0.0642 |
SK-BR-3 | Erlotinib | 0.1810 |
SK-BR-3 | Alvocidib | 1.3211 |
SK-BR-3 | Foretinib | 0.7404 |
SK-BR-3 | Pictilisib | 0.8859 |
SK-BR-3 | GDC-0980 | 1.0375 |
SK-BR-3 | Gefitinib | 0.4868 |
SK-BR-3 | Geldanamycin | 1.1190 |
SK-BR-3 | GSK 690693 | 0.4184 |
SK-BR-3 | GSK1059615 | 0.7264 |
SK-BR-3 | GSK1904529A | 0.0548 |
SK-BR-3 | Omipalisib | 1.2487 |